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Аbstract
Introduction. Nosocomial pneumonia (NP) is the second leading frequency and mortality among nosocomial infections. NP 
is a frequent complication of severe traumatic brain injury (TBI). The difficulty in diagnosis and monitoring of disease NP on the 
background of TBI is that the usual signs NP “masked” manifestations of the underlying disease.
The aim of our study was to improve the diagnosis and assess the effectiveness of the treatment of nosocomial pneu-
monia with clarithromycin by studying of serum interleukins in patients with nosocomial pneumonia on the background of 
traumatic brain injury.
Materials and methods. We determined levels of TNFα, IL-4, IL-6, IL-8, IL-10. We examined 45 patients with isolated 
TBI, 44 patients with NP (standard treatment scheme), 49  patients with NP, each therapy with clarithromycin. The control group 
was 33 relatively healthy people.
Conclusions. The study revealed a significant increase in the concentration of interleukin TNFα, IL-6, IL-8, IL-10 in the 
serum of patients with NP on the background of TBI compared with patients with isolated TBI and healthy individuals. Our study 
found significantly lower concentrations of interleukin TNFα, IL-6, IL-8, IL-10 in the serum of patients after treatment with the 
addition of clarithromycin compared with patients with standard therapy.
Keywords: nosocomial pneumonia, traumatic brain injury, diagnosis, cytokines, clarithromycin.
DOI: 10.21303/2504-5679.2017.00279  © Anastasiia Ilchenko
1. Introduction
Nosocomial pneumonia (NP) is the second in frequency and the first in mortality among 
nosocomial infections. NP is one of the most common and dangerous infectious complications 
of severe traumatic brain injury (TBI). According to many researchers, GP develops in 20−60 % 
of cases of TBI. The clinical diagnosis of nosocomial pneumonia, diseases of the central nervous 
system in general and in particular TBI, remains a challenge that continues to develop [1−5]. Late 
diagnosis is one of the causes of complications and lethal outcome in this group of patients with 
clinical signs of pneumonia, hidden symptoms of the underlying disease, severity of general cere-
bral and focal neurological symptoms [1, 4−7]. Clinical signs NP include a local lung inflammation, 
extrapulmonary manifestations of pneumonia, laboratory and radiological changes; all the criteria 
listed above are nonspecific. Fever and leukocytosis often accompany an isolated head injury. Pu-
rulent sputum from the trachea may indicate only the colonization of the upper respiratory tract. 
Not informative conventional X-ray may be associated with localized pneumonic foci in remote 
places [8−9]. Complication of NP diagnosis in this patient and the severity of the underlying dis-
ease, neurological symptoms and the need for prolonged use of mechanical ventilation are typical. 
That is why the search for markers of inflammation for the diagnosis and monitoring of NP on the 
background of TBI using informative and, if possible, non-invasive methods is urgent [1, 10−13].
Among the various pathogenic factors contributing to the occurrence, effects and peculiar-
ities of pulmonary pathology, many authors identify violations of immunological reactivity and 
imbalance mediators of intercellular interactions. In recent years the role of cytokines as key me-
diators of inflammation is widely discussed [14, 15]. The main mediators recognized damaged 
lung tumor necrosis factor alpha (TNFα), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 
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8 (IL-8); among cytokines with anti-inflammatory properties the leading role is played by interleu-
kin 10 (IL-10). In diseases of the lung cytokines the data, included in the infectious-inflammatory 
process at their own immune effector mechanisms and managers, largely determine the direction, 
severity and outcome of pathological process [1−2, 16−19].
Relatively pneumonia, as a separate nosology, is enough publications that clearly confirm 
the production of interleukins, both locally and in the systemic circulation in response to lipopoly-
saccharide complexes microorganisms [3, 7, 18−20]. According to the scientists, determination of 
the level of interleukin has diagnostic value, because the concentration of cytokines in the blood ad-
equately reflects the severity of inflammation [7, 8, 15, 17]. However, to date there is no study of the 
diagnostic role of cytokines in nosocomial pneumonia against the background of TBI. Therefore, 
to assess the pathogenetic role of interleukins and their diagnostic value, we studied the contents of 
TNFα, I IL-6 and IL-8 in serum of patients with NP on the background of TBI and their changes in 
the dynamics of the treatment process [1, 5, 19−21].
2. Aim 
Improve the diagnosis and assess the effectiveness of the treatment of nosocomial pneumo-
nia by studying of serum interleukins in patients with nosocomial pneumonia on the background 
of traumatic brain injury.
3. Materials and Methods
The study was conducted in 138 patients aged 18 to 83 years, who were treated in de-
partments of intensive care neurosurgery and neurosurgery Zhytomyr Regional Clinical Hospital, 
named after O. F. Herbachevsky during 2013−2016.
The composition of Group 1 included 45 patients with severe TBI. The patients whose trau-
matic brain injury was complicated by the development of NP, were divided into two identical groups 
depending on the treatment. The structure of the second group included 44 patients with NP treated 
with medication according to the standard scheme (ceftazidime and levofloxacin). The structure of 
the Group 3 contained 49 patients who received standard therapy in addition to clarithromycin 500 
mg two times daily by intravenous infusion. There is little known effect of clarithromycin in cases 
NP with regard to its indirect antimicrobial and immunomodulatory properties. The inclusion of im-
munomodulating treatment, contributing to the elimination of cytokine imbalance, as a component of 
adjuvant therapy in the pathogenesis NP is reasonable. Duration of treatment was 10 days. Patients of 
2 and 3 groups underwent the interleukins control again on 10th day of treatment.
 Among the Group 1 of patients 38 people (84.5 %) were male, 7 persons (15.5 %) − women. 
The average age of patients in Group 1 was 49,2±15,2 years.  Among patients Group 2 − in accordance 
36 men (81.8 %) and 8 women (18.2 %) , among patients of Group 3 − 41 persons (83.7 %) – men, 
8 people (16.3 %) − women . The average age of patients in this group was 48,2±16,7 years. Gender 
differences in the structure of the groups were not statistically significant (p> 0.05).
The diagnosis of pneumonia is established according to international recommendations and 
the current Ukrainian Protocol diagnosis and treatment of pulmonary disease in adults (Ukraine 
№ 128 from 19.03.2007).
Determination of  the levels of interleukin TNFα, IL-6, IL-8, IL-10 in serum was performed 
by ELISA using standard reagent kits A-8756 “TNFα-IFA-BEST”, measuring range: 0–250 pg/ml; 
A-8768 “IL-6-IFA-BEST”, measuring range: 0–300 pg/ml; A-8762 “IL-8-IFA-BEST”, measuring 
range: 0-250 pg/ml; A-8774 “IL-10 -IFA-BEST” measurement range: 0–500 pg/ml; produced by 
“Vector-Best”, Russia. Settings regional standards were determined in 33 adult healthy subjects. 
The average age of 35,4±16,1 years, of which – 30 (87.9 %) men and 4 (12.1 %) women (control 
group). Blood sampling was carried out in equal conditions (in the morning on an empty stomach 
in the quantities of 5 ml). The data were analyzed using the standard methods of statistical analysis 
using a personal computer using the application package Microsoft Excel, Statistica 6. 0. Statistical 
analysis of the differences between the groups with regard to the nature of distribution was carried 
out using non-parametric test Mann-Whitney.
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4. Results 
The following results of interleukins study were obtained. The were received the following in-
dicators of regional norms: TNFα – 0,94±0,24 pg/ml (range 0.40–1,28 pg/mL), IL-6 – 1,24±0,22 pg/ml 
(range 0.90 to 1.62 pg/mL), IL-8 – 1,50±0,61 pg/ml (range 0.5 to 2.6 pg/ml), IL-10 – 1,61±0 54 pg/ml 
(range 0.7 to 3.0 pg/ml). 
In group 1 were the following results interleukins: TNFα – 3,21±0,67 pg/ml, IL-6 – 4,88± 
±1,65 pg/ml, IL-8 – 3,93±0,95 pg/ml, IL-10 – 4,63±3,07 pg/ml. 
The results of interleukins in groups 2 and 3, compared with healthy people, are presented 
in Table 1.
Table 1
Comparison of interleukins in groups 2, 3 and healthy people
Parameter Group 2 Group 3 Healthy person р 2-3* р H/P-2** Р H/P-3**
TNFα, pg/ml 6,42±5,41 6,96±6,06 0,94±0,24 >0,05 <0,0001 <0,0001
IL-6, pg/ml 59,04±69,52 65,84±82,14 1,24±0,22 >0,05 <0,0001 <0,0001
IL-8, pg/ml 53,11±61,55 49,79±60,12 1,50±0,61 >0,05 <0,0001 <0,0001
IL-10, pg/ml 13,60±21,15 12,72±19,91 1,61±0,54 >0,05 <0,0001 <0,0001
Note: * – statistically insignificant differences between the second and the third groups (p>0.05); ** – statistically significant differ-
ences between the healthy person and second or third groups (p<0,0001)
The results of interleukins in groups 2 and 3 before treatment and after treatment, compared 
with Group, are presented in Table 2.
Table 2
Comparison of interleukins in Group 2 and Group 3 with Group 1
Parameter Group 1
Comparison Group 1 
with Group 2 Before 
treatment 
Comparison Group 
1 with Group 2 After 
treatment
Comparison Group 1 
with Group 3 Before 
treatment
Comparison Group 
1 with Group 3 After 
treatment
TNFα, pg/ml 3,213±0,673 0,005* 0,006* 0,028* 0,359#
IL-6, pg/ml 4,888±1,659 0,001* 0,023* 0,001* 0,430#
IL-8, pg/ml 3,938±0,959 0,001* 0,004* 0,001* 0,133#
IL-10, pg/ml 4,638±3,075 0,075# 0,017* 0,011* 0,133#
Note: # – statistically insignificant differences (p>0.05); * – statistically significant differences (p <0.05)
Statistical comparison of the reliability of differences between groups 2 and 3 before treat-
ment and after treatment (Table 3).
Table 3
Statistical comparison between groups  2 and 3 before treatment and after treatment
Parameter Group 2 Group 3 p***Before treatment After treatment p* Before treatment After treatment p**
TNFα,
pg/ml 
6,420±
±5,413
5,285±
±10,261
0,502 6,960±
±6,062
3,545±
±1,044
0,118 0,002
IL-6,
pg/ml 
59,040±
±69,523
15,245±
±9,921
0,264 65,840±
±82,143
6,480±
±3,953
0,004 0,004
IL-8,
pg/ml 
53,110±
±61,549
12,990±
±8,130
0,118 49,790±
±60,116
5,970±
±3,416
0,001 0,007
IL-10, 
pg/ml
13,600±
±21,152
10,060±
±9,290
0,823 12,720±
±19,908
7,445±
±5,166
0,823 0,330
Note: p* – statistically differences between the before treatment and after treatment in the second groupe; p** – statistically differ-
ences between before treatment and after treatment in the third group; p*** – statistically differences between the second group and 
the third group after treatment (p<0.05 – statistically significant differences)
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6. Discussion 
We received the values of control group of people in line with the average, obtained in the 
examination of serum of healthy donors by the manufacturer of test systems “Vector-Best”.
Increased levels of cytokines in the group 1 relative to healthy subjects was statistically 
significant (p<0.0001), which is associated with the likely reaction to trauma and stress, but signifi-
cantly lower than in groups 2 and 3. 
The increase of the level of interleukin TNFα, IL-6, IL-8 in group 2 and 3 before treatment 
is significantly higher than in group 1 (p<0.05). In group 2 after treatment (standard therapy) inter-
leukin difference in levels compared with group 1 remains statistically significant (p<0.05). How-
ever, the results of interleukin TNFα, IL-6, IL-8 in group 3 after treatment show no statistically 
significant difference compared to a group 1 (p>0.05). This shows the effectiveness of complemen-
tary therapy with clarithromycin, which was performed in group 3. The difference is statistically 
significant TNFα, IL-6, IL-8 in groups 2 and 3 after treatment (p <0.05).
7. Conclusions
The study revealed a significant increase in the concentration of interleukin TNFα, IL-6, 
IL-8, IL-10 in the serum of patients with NP on the background of TBI compared with patients with 
isolated TBI and healthy individuals.
Quantitative changes in the concentration of serum interleukins in patients with NP on the 
background of TBI allow you to use these markers as additional laboratory criterion in specifying 
the diagnosis in these patients. Determination of cytokine status can be used to improve diagnosis 
in patients with TBI threatening complications such as nosocomial pneumonia.
In groups 2 and 3 (patients with NP) before treatment no significant difference in the levels of 
interleukins was revealed. So Groups 2 and 3 are identical by the level of cytokines TNFα, IL-6, IL-8, 
IL-10. However, our study found significantly lower concentrations of interleukin TNFα, IL-6, IL-8 
in the serum of patients of Group 3 after treatment with the addition of clarithromycin compared with 
patients Group 2 (standard therapy).
Thus the use of clarithromycin in the treatment of nosocomial pneumonia on the back-
ground TBI has been effective, as it is evidenced by significant decrease in levels of interleukin 
TNFα, IL-6, IL-8. The analysis of cytokine status is effective for monitoring the effectiveness of 
treatment of nosocomial pneumonia on the background of TBI.
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